Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmark innovation. Early studies suggest that immune checkpoint inhibition might also be effective in patients with gastrointestinal cancer. To improve the efficacy of immunotherapy, different strategies a...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 March 2016
|
| In: |
European journal of cancer
Year: 2016, Jahrgang: 59, Pages: 160-170 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2016.02.020 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2016.02.020 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001362 
|
| Verfasserangaben: | Markus Moehler, Maike Delic, Katrin Goepfert, Daniela Aust, Heike I. Grabsch, Niels Halama, Bernd Heinrich, Catherine Julie, Florian Lordick, Manfred P. Lutz, Murielle Mauer, Maria Alsina Maqueda, Hansjoerg Schild, Carl C. Schimanski, Anna-Dorothea Wagner, Arnaud Roth, Michel Ducreux |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1679764438 | ||
| 003 | DE-627 | ||
| 005 | 20240323101357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191024s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2016.02.020 |2 doi | |
| 035 | |a (DE-627)1679764438 | ||
| 035 | |a (DE-599)KXP1679764438 | ||
| 035 | |a (OCoLC)1341248516 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Möhler, Markus |e VerfasserIn |0 (DE-588)112161955X |0 (DE-627)874401909 |0 (DE-576)480916063 |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy in gastrointestinal cancer |b Recent results, current studies and future perspectives |c Markus Moehler, Maike Delic, Katrin Goepfert, Daniela Aust, Heike I. Grabsch, Niels Halama, Bernd Heinrich, Catherine Julie, Florian Lordick, Manfred P. Lutz, Murielle Mauer, Maria Alsina Maqueda, Hansjoerg Schild, Carl C. Schimanski, Anna-Dorothea Wagner, Arnaud Roth, Michel Ducreux |
| 264 | 1 | |c 31 March 2016 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.10.2019 | ||
| 520 | |a The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmark innovation. Early studies suggest that immune checkpoint inhibition might also be effective in patients with gastrointestinal cancer. To improve the efficacy of immunotherapy, different strategies are currently under evaluation. This review summarises the discussion during the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Translational Research Meeting in Mainz in November 2014 and provides an update on the most recent results of immune therapy in gastrointestinal cancers. Knowledge of potential relationships between tumour cells and their microenvironment including the immune system will be essential in gastrointestinal malignancies. In this context, the density of T cell infiltration within colorectal cancer metastases has been associated with response to chemotherapy, and a high expression of programmed cell death ligand 1 (PD-L1) in advanced gastric cancer has been related with poor prognosis. Effective targets might include neo-antigens encoded from genes carrying tumour-specific somatic mutations. Tailored immunotherapy based on such mutations could enable the effective targeting of an individual patient’s tumour with vaccines produced on demand. Other strategies considering checkpoint inhibitors have shown efficacy by targeting cytotoxic T-lymphocyte-associated protein 4 and PD-1 or PD-L1. DNA mismatch repair-deficient tumours appear to be potentially the best candidates for these therapies. Finally, the combination of oncolytic viruses with immunotherapy might boost antitumour activity as well. Further evaluation of these promising immunological therapeutic approaches will require large prospective clinical studies. | ||
| 650 | 4 | |a Checkpoint inhibitors | |
| 650 | 4 | |a Gastrointestinal cancer | |
| 650 | 4 | |a Immunotherapy | |
| 700 | 1 | |a Halama, Niels |d 1977- |e VerfasserIn |0 (DE-588)13087325X |0 (DE-627)507228723 |0 (DE-576)251045706 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 59(2016), Seite 160-170 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Immunotherapy in gastrointestinal cancer Recent results, current studies and future perspectives |
| 773 | 1 | 8 | |g volume:59 |g year:2016 |g pages:160-170 |g extent:11 |a Immunotherapy in gastrointestinal cancer Recent results, current studies and future perspectives |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2016.02.020 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804916001362 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191024 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 13087325X |a Halama, Niels |m 13087325X:Halama, Niels |d 910000 |d 910100 |e 910000PH13087325X |e 910100PH13087325X |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1679764438 |e 3526978085 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1679764438","note":["Gesehen am 24.10.2019"],"name":{"displayForm":["Markus Moehler, Maike Delic, Katrin Goepfert, Daniela Aust, Heike I. Grabsch, Niels Halama, Bernd Heinrich, Catherine Julie, Florian Lordick, Manfred P. Lutz, Murielle Mauer, Maria Alsina Maqueda, Hansjoerg Schild, Carl C. Schimanski, Anna-Dorothea Wagner, Arnaud Roth, Michel Ducreux"]},"relHost":[{"part":{"text":"59(2016), Seite 160-170","pages":"160-170","extent":"11","year":"2016","volume":"59"},"titleAlt":[{"title":"EJC online"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"display":"European School of Oncology","role":"isb"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"pubHistory":["28.1992 -"],"recId":"266883400","disp":"Immunotherapy in gastrointestinal cancer Recent results, current studies and future perspectivesEuropean journal of cancer"}],"title":[{"title":"Immunotherapy in gastrointestinal cancer","subtitle":"Recent results, current studies and future perspectives","title_sort":"Immunotherapy in gastrointestinal cancer"}],"person":[{"role":"aut","family":"Möhler","display":"Möhler, Markus","given":"Markus"},{"role":"aut","given":"Niels","display":"Halama, Niels","family":"Halama"}],"physDesc":[{"extent":"11 S."}],"id":{"eki":["1679764438"],"doi":["10.1016/j.ejca.2016.02.020"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"31 March 2016","dateIssuedKey":"2016"}]} | ||
| SRT | |a MOEHLERMARIMMUNOTHER3120 | ||